Regulatory turbulence is reshaping shelves as the TGA removes ingredients while creating new ones — and private label supplements are capturing the trust gap.
The March–May 2026 period is defined by three converging forces: (1) the TGA simultaneously opening the NMN longevity category and consulting on removing Andrographis from OTC listed medicines, creating both a new shelf and a void in cold/flu; (2) Coles' Ultralife brand winning two 2026 Product of Year awards in health, signalling that grocery private label now commands the same trust as branded supplements; and (3) the GLP-1 wave — with 39.7% of Australian adults now estimated eligible for weight management medication — creating sustained commercial demand for adjacent consumer health products around protein, fibre, and muscle preservation.
Andrographis Removal Reshapes Cold/Flu
The TGA's April 2026 consultation — backed by RACGP — to remove Andrographis from permitted ingredients will force reformulation of ~84 listed cold/flu products, creating a white-space moment for Echinacea-only, zinc-C-D3, and elderberry-based immune formulas heading into winter season.
NMN Longevity Launches at Scale
Australia became the first country globally to regulate NMN for therapeutic goods (TGA, December 2025). Chemist Warehouse rolled out exclusive pharmacy distribution from January 2026 with brands at $39.99–$59.99, deliberately undercutting global market pricing to drive category education and accessibility.
Grocery Private Label Wins Consumer Trust
Coles' Ultralife brand swept the 2026 Product of Year health categories (Ashwagandha and Hair Skin Nails Gummies). With private label now at 68% of POY wins and Macro organic health reporting 12% growth at Woolworths, consumers are selecting grocery supplements over branded alternatives at record rates.
With the Andrographis consultation period closed and a decision pending, brands with complementary immune formulations need to act now — ranging new SKUs before winter season peaks in June–July. The window to capture displaced shelf space is 8–12 weeks.
Healthy Ageing & Longevity (VMS)
Rising| Trending now | NMN (NAD+ precursor) launching as an exclusive pharmacy category at CWH; longevity stacks (NMN + resveratrol + berberine) building consumer interest; cellular beauty ingredients (ergothioneine, quercefit, ceramosides) entering premium pharmacy ranging |
| Consumer needs | Proactive healthy ageing; energy production and DNA repair; "stay young longer" rather than treat illness; biohacking adjacent shoppers and mainstream 45–65 cohort |
| Ingredients / formats | NMN 250–500mg capsules; Swisse Nutra Cellular range blending NMN-adjacent ingredients; berberine gaining alongside ashwagandha; collagen evolving from cosmetic to multi-benefit joint + gut + skin |
| Notable brands | Melrose FutureLab (NMN 500mg, $59.99 at CWH), Wanderlust Biohack (NMN + Longevity, $49.99 at CWH), Swisse Nutra Cellular Beauty (exclusive CWH), Genetic Labs Australia (longevity stacks online) |
| Pharmacy vs grocery | Strongly pharmacy-led — CWH exclusivity on NMN; TGA framework creates pharmacy credibility moat. Grocery represented via Coles Ultralife Ashwagandha and Blackmores Ashwagandha at Coles. |
| Seasonality / timing | Autumn/winter indoor season aligns with energy and immunity; Woolworths "Health of the Nation" survey names longevity as #2 health goal for 2026 — the consumer mindset is right now |
| Commercial implication | CWH's NMN education play positions the category for a 3–5 year growth trajectory; secondary sponsors face a 2027 exclusivity timeline — brands need to secure authorisation now to enter this market |
OTC Immunity, Cold & Flu
Disrupted| Trending now | Andrographis TGA removal consultation creating imminent reformulation crisis for ~84 listed medicines; 2026 flu season already active with new H3N2 Subclade K strain spreading earlier; slow vaccine uptake in priority groups creating OTC demand window |
| Consumer needs | Preventive immunity before winter peaks (June–August); cold/flu symptom relief without prescription; fast-acting formats — rapi-melt, effervescent, liquid; family self-care (children's dosing) |
| Ingredients / formats | Echinacea (safe without Andrographis), Vitamin C, Zinc, Olive Leaf Extract, Elderberry, Vitamin D3; Blackmores Immune Rapi-Melt (fast-dissolve, new format); Echinacea ACE + Zinc; effervescent and powder formats growing |
| Notable brands | Blackmores (Immune Rapi-Melt new launch, Bio C range); Swisse (Ultiboost Calm + Sleep, Probiotic + Immune); BioCeuticals ArmaForce (Andrographis-containing — at risk); Brauer, Fusion Health |
| Pharmacy vs grocery | Pharmacy leads on efficacy-positioned products; grocery captures Vitamin C and Zinc mainstream. Andrographis removal primarily hits pharmacy-stocked listed medicines. |
| Seasonality / timing | Autumn 2026 is the critical ranging window. 25,430 influenza cases already recorded in Q1 2026 — demand is materialising 4–6 weeks ahead of typical southern hemisphere pattern |
| Commercial implication | Brands without Andrographis in their immunity range have a competitive window right now — shelf space will move once the TGA decision is finalised. Echinacea-only and zinc-vitamin C combinations will benefit most |
Sleep, Stress & Magnesium
Rising| Trending now | Magnesium glycinate powders surging over capsule formats; JSHealth Advanced Magnesium+ powder a Priceline standout; melatonin import crackdown creating demand for non-melatonin registered sleep products; ACMS consulting on adult OTC melatonin rescheduling |
| Consumer needs | Sleep quality without a prescription; stress and cortisol management; evening routine supplements (calm wind-down ritual); women's hormonal balance (magnesium + adaptogens); "clean label" calming ingredients |
| Ingredients / formats | Magnesium glycinate (dominant); magnesium L-threonate (cognitive-sleep crossover); ashwagandha (adaptogen, now in grocery via Coles Ultralife and Blackmores); L-theanine; passionflower; valerian; powder-in-water ritual format overtaking capsules |
| Notable brands | JSHealth (Advanced Magnesium+ powder, Priceline); Switch Nutrition (Mag Gly capsules and powder); Swisse Ultiboost Magnesium Glycinate (Coles); Vitaceuticals Magzorb (Coles); Herbs of Gold (independent pharmacy) |
| Pharmacy vs grocery | Pharmacy leads on clinical magnesium and premium formulations; grocery is capturing standard magnesium tablets and glycinate capsules via Swisse and Blackmores. Powder formats still primarily pharmacy. |
| Seasonality / timing | Autumn daylight saving end (April) disrupts sleep cycles nationally — the highest-intent moment for sleep supplement purchases is now through June |
| Commercial implication | The melatonin TGA alert has redirected consumer search to registered sleep supplements. Any brand with an AUST L number and a clear sleep/magnesium story benefits from this displacement immediately |
Weight Management & GLP-1 Adjacent
Rising| Trending now | GLP-1 eligibility confirmed at population scale — consumer health adjacency building around muscle preservation, protein pacing, fibre satiety (→ see Market Signals for full research detail) |
| Consumer needs | Appetite and satiety support; lean muscle preservation (GLP-1 users lose muscle mass); high-protein, high-fibre nutrition; metabolic health markers (blood sugar, blood pressure — addressed via Priceline SiSU stations); sustainable weight management without injections |
| Ingredients / formats | Whey and plant protein (muscle preservation on GLP-1 protocol); creatine (muscle maintenance); fibre supplements (psyllium, inulin, glucomannan); berberine (blood sugar positioning); meal replacement high-protein formats |
| Notable brands | Swisse Ultiboost (collagen + shred format at Coles), Nutra Organics (functional protein blends), Happy Way (plant protein), Musclepharm, Switch Nutrition; berberine entrants via longevity stack positioning |
| Pharmacy vs grocery | Pharmacy captures GLP-1 adjacency via clinical positioning (berberine, protein with pharmacist recommendation); grocery captures high-protein, high-fibre formats in the health aisle and fresh foods. |
| Seasonality / timing | Post-summer (March–May) is a sustained weight-management intent period in Australia before winter comfort-food habits set in. The PBAC review adds urgency for brands to establish positioning before oral GLP-1 reshapes the category |
| Commercial implication | Brands positioning around GLP-1 adjacency (muscle support, satiety, metabolic) have a 12–18 month window before oral semaglutide arrives and resets consumer expectations. Category education investment now will compound |
Beauty-from-Within & Skincare Supplements
Rising| Trending now | Cellular beauty positioning (Swisse Nutra Cellular range at CWH); K-beauty brands entering Priceline (INNISFREE, Beauty of Joseon, Bubble); collagen evolving to multi-benefit (joint + gut + skin); NAD+ convergence between longevity and beauty supplements |
| Consumer needs | Skin hydration and elasticity from inside out; hair and nail health; anti-ageing without aesthetic procedures; "cellular vitality" story for 35–55 women; beauty supplements that also deliver energy and gut benefit |
| Ingredients / formats | Marine collagen peptides (Vida Glow dominant in AU); UC-II collagen (joint-focused); hyaluronic acid, biotin, zinc, sea moss; Ceramosides; ergothioneine; astaxanthin; beauty gummies accelerating (no-sugar formats) |
| Notable brands | Vida Glow (marine collagen, premium pharmacy), Swisse Nutra Cellular Beauty (CWH exclusive), Swisse Glam Bites (no-sugar beauty gummies), The Beauty Chef, Nutra Organics, JSHealth (hair-skin-nails range at Priceline) |
| Pharmacy vs grocery | Pharmacy leads premium beauty supplements; grocery capturing mainstream collagen (Nature's Way Collagen Shots, Swisse Ultiboost Collagen at Coles); beauty gummies entering grocery via Haircarebear and private label |
| Seasonality / timing | Autumn is the post-summer "repair" window — consumers shifting from sun damage to skin restoration. The Priceline K-beauty launch creates a beauty supplement halo effect in store |
| Commercial implication | The cellular beauty story (Swisse Nutra) creates a new premium tier above standard collagen. Brands that can bridge longevity + beauty + clinical evidence in a single SKU own a significant white space |
Sports, Protein & Active Nutrition
Stable / Rising| Trending now | Protein expanding beyond gym users to women, healthy agers, and GLP-1 muscle preservation cohort; "fibre-maxxing" emerging as a trend alongside protein pacing (20–30g per meal); protein + synbiotic combination formats in development globally |
| Consumer needs | Muscle recovery and lean mass maintenance; satiety and weight management; gut health support alongside protein; clean-label and plant-based options; convenient RTD and on-the-go formats |
| Ingredients / formats | Whey protein (dominant); pea protein (fastest growing); creatine crossing into women's and healthy ageing occasions; electrolytes (moving from sports to everyday hydration); protein + fibre blends emerging |
| Notable brands | Switch Nutrition, Protein Supplies Australia, Happy Way, Nutra Organics (wholefood protein), Muscle Nation, Optimum Nutrition; Swisse Ultiboost Collagen + Shred crossover format |
| Pharmacy vs grocery | Grocery increasingly important — Woolworths and Coles expanding protein bar and RTD shelving. Pharmacy captures premium performance and recovery supplements with pharmacist credibility. |
| Seasonality / timing | Autumn gym season: new year gym joiners move to a sustained maintenance phase in March–May; AFL/NRL seasons drive sports nutrition demand nationally |
| Commercial implication | The GLP-1 muscle preservation narrative gives protein brands a clinically credible positioning that moves beyond aesthetics — this extends the addressable market significantly to 40+ demographics |
| Dimension | Pharmacy (CWH, Priceline, Terry White) | Grocery (Woolworths, Coles, Aldi) |
|---|---|---|
| Category exclusives | NMN (CWH exclusive pharmacy retailer); Swisse Nutra Cellular range (CWH exclusive); Priceline exclusive brands (Software Skin, Clear Skincare, Georgiemane) | Coles Ultralife (private label supplements + vitamins); Woolworths Macro organic health; Aldi supplement range |
| Regulatory positioning | TGA AUST L/R framework creates pharmacy credibility for NMN, sleep, and immunity supplements; pharmacist recommendation drives conversion | Grocery OTC supplements face no consultation requirement — advantage in accessibility but less clinical positioning power |
| Pricing strategy | CWH below-market NMN pricing as a category-building play (→ see Market Signals); Priceline $10 Tuesday viral loyalty deal | Private label supplements 30% cheaper than branded equivalents (Woolworths claim); Coles Ultralife positioned at accessible price points with POY credibility |
| Health services integration | Priceline SiSU Health Stations measuring BMI, body composition, blood pressure, heart rate, diabetes markers — turning stores into health destinations | Woolworths "Health of the Nation" platform with Body+Soul editorial integration; healthylife.com.au digital supplement hub |
| Digital / loyalty | Priceline Spirit loyalty finalist for Top Loyalty Program; $10 Tuesday deal nominated for Top Viral Moment; CWH app and Scan & Go | Everyday Rewards (Woolworths) deeply embedded; Coles Plus; 80% of Australians now multi-retailer shopping monthly |
| Beauty & wellness convergence | Priceline launching K-beauty: INNISFREE, Beauty of Joseon, Bubble (Gen Z brand); pharmacy beauty supplement adjacency growing | Woolworths expanding health aisle; Coles Finest premium positioning; beauty supplement gummies entering grocery shelf |
| Online competitive pressure | Amazon AU PPC impression share peaked at 18.62% in AU Retail Health & Beauty (March 2026), with CWH declining to 13.55% — digital share eroding | Coles Uber Eats on-demand grocery delivery live (Dec 2025); grocery health products increasingly purchased in 30-minute delivery windows |
| Winter immunity positioning | Pharmacy leads with OTC cough/cold/flu with pharmacist consultation — but Andrographis disruption creates urgency to reformulate and re-educate shelf | Grocery captures Vitamin C, Zinc, and cold/flu mainstream with Swisse, Blackmores, and own-label — less exposure to Andrographis disruption |
Following TGA approval of NMN (nicotinamide mononucleotide) as a permitted therapeutic ingredient in December 2025 — the first country globally to regulate it — Chemist Warehouse began nationwide rollout of NMN supplements from January 8, 2026. Products available include Melrose FutureLab NMN 500mg capsules ($59.99) and Wanderlust Biohack NMN + Longevity ($49.99, containing NMN + CoQ10 + alpha lipoic acid + green tea). Price points are significantly lower than comparable products in Singapore ($79 USD) and the US. CWH is the exclusive pharmacy retailer; secondary brand sponsors must obtain authorisation from primary sponsor SyncoZymes (Shanghai) until December 2027. A University of Sydney study on NMN's efficacy in humans will commence in 2026.
The TGA published its proposal on April 9, 2026 to remove Andrographis paniculata from the Permissible Ingredients Determination — the list of low-risk ingredients permitted in listed medicines. The review found Andrographis linked to anaphylaxis, with international reporting showing disproportionately high rates compared to Echinacea. Approximately 84 listed medicines containing Andrographis are currently on the ARTG, available from pharmacies, supermarkets, and health food stores. The RACGP Expert Committee on Quality Care formally supported the TGA's proposal, citing limited evidence of benefit for cold/flu symptoms. Consultation closed April 30, 2026. ABC News, NutraIngredients, Bond University RACGP commentary, TGA media release, April 2026.
The TGA's Pharmacy Board April 2026 newsletter detailed a safety alert on imported, unregistered melatonin: lab testing found one product with more than 400% of the labelled melatonin content and another with none detectable. iHerb suspended melatonin sales to Australia; the TGA directed the Australian Border Force to seize and destroy intercepted imports. Separately, the ACMS convened in March 2026 to consult on rescheduling melatonin — potentially allowing OTC sale to adults without prescription (aligning with New Zealand, which made this change in October 2025). Poisons hotlines recorded approximately 1,500 calls about children ingesting melatonin in 2025. Sources: Pharmacy Board Newsletter April 2026, TGA consultation March 2026, ABC News September 2025.
Coles' private label Ultralife brand won the 2026 Product of Year (POY) in both Health & Wellness (Supplements) — Ultralife Ashwagandha Tablet 60T — and Health & Wellness (Vitamins) — Ultralife Adult Hair Skin Nails Gummies. The POY process is judged by over 5,000 Australian consumers and validated by NielsenIQ. In total, 27 of 40 POY winners in 2026 were Coles or Woolworths private label products (68%, up from 55% the prior year). NielsenIQ research found 74% of Australians have a personal health goal, with strongest preferences for no-sugar (37%), high protein (36%), and gut health (20%). Sources: NielsenIQ/Product of Year, October 2025; Food & Drink Business, FoodMag, 2025.
JSHealth Advanced Magnesium+ powder was named a standout seller in Priceline's Beauty Prescription Live showcase (March 2026, covering Priceline's 470 stores). Magnesium glycinate is simultaneously among Australia's most searched supplement categories, with multiple format entries: Switch Nutrition Mag Gly capsules (~$0.44/cap), Swisse Ultiboost Magnesium Glycinate powder at Coles, Vitaceuticals Magzorb 500mg at Coles, and Herbs of Gold in independent pharmacy. The global trend towards magnesium glycinate — globally +33% search volume — is clearly landing in the AU market. The format shift from capsules to dissolvable evening powders reflects a ritualisation of sleep and stress supplementation. Sources: Priceline Beauty Prescription Live; ecotraders.com.au buyer guide 2026; Coles.com.au range data.
A preprint published March 19, 2026 (medRxiv) provides the first population-level estimate of GLP-1 eligibility in Australia, using 2022 ABS National Health Survey data. The study finds 39.7% of Australian adults are eligible under current TGA-approved weight management indications for GLP-1 receptor agonists (Wegovy, Saxenda, Mounjaro). Up to 4.3% of those also meet criteria for secondary cardiovascular prevention. The PBAC published a review of equitable access to GLP-1 obesity treatments in the same period. Oral semaglutide (Rybelsus for obesity) is expected to reach Australia by late 2026 or early 2027. Sources: medRxiv March 2026; abbyhealth.app; Hormones Australia, 2026; Abby Health, 2026.
H&H Group (Swisse's parent) launched the Swisse Nutra Cellular Beauty Range exclusively at Chemist Warehouse, targeting cellular health rather than surface-level cosmetic supplementation. The range includes Cellular Skin Hydration and Cellular Hair Growth formulas for men and women, plus products for cellular energy, metabolism, joint mobility, and cognition. Key ingredients include Quercefit (quercetin), Lute-gen (lutein), pumpkin seed oil, Ceramosides, Berbevis (berberine), and UC-II Type II Collagen. The cellular beauty positioning reflects a global trend identified by Boston Consulting Group as "beauty-from-within going cellular and age-agnostic." Source: NutraIngredients, February 2026.
Australian Pharmacist reported that 25,430 influenza cases were recorded in Q1 2026, against a backdrop of 48,641 cases in Q1 2025 and 1,738 influenza deaths in that year. A new H3N2 Subclade K strain is spreading earlier and faster than typical flu season patterns. WA has launched government-funded FluMist nasal vaccine for children 2–11 years across pharmacies. Flu vaccine uptake in 2026 is described as "concerningly low" in priority groups. The early season and slow vaccination rate creates a substantial OTC immunity supplement demand window, complicated by the Andrographis regulatory situation. Source: Australian Pharmacist, 2026.
News Corp Australia's Health of the Nation 2026 report (n=3,000 Australians, Woolworths as presenting partner for a third year) found: happiness is the #1 wellbeing goal, followed by longevity ("staying healthy as I age") — ahead of weight management and mental health. 45% of Australians said healthy ageing is their reason for drinking less alcohol. Nearly two-thirds eat with at least one health goal in mind (gut health, energy, immunity, mental health). Woolworths MD Annette Karantoni emphasised the retailer's commitment to "simple, affordable, and healthier options." Source: News Corp Australia / Woolworths, January 2026; AdNews, January 2026.
Adthena's March 2026 AU Retail Health & Beauty PPC report shows Amazon.com.au's impression share peaked at 18.62% on March 19, exceeding Chemist Warehouse's range of 11.3–14.4% throughout the month. CWH ended March at 13.55%, down from peaks. Priceline and Sephora maintained 1.72% and 1.68% respectively. Woolworths was stable at ~4% and iHerb at ~1.4% for the month. Amazon's digital advertising capability is now outpacing pharmacy incumbents at the point of consumer consideration. Source: Adthena AU Retail Health and Beauty Market Share Analysis, March 2026.
Priceline Pharmacy announced the addition of K-beauty brands INNISFREE and Beauty of Joseon to its national network, alongside US Gen Z brand Bubble and female-founded brands Yours Only and Daily Skincare. The retailer runs 470 stores nationally and highlighted that 1,800 new products were launched over the prior year. The K-beauty entry signals Priceline's push to attract Gen Z and millennial consumers and reposition as a full-spectrum health and beauty destination rather than a pharmacy-first retailer. Source: Priceline Beauty Prescription Live, March 2026; Melissa Hoyer, March 2026; Wesfarmers Health newsroom.
Swisse extended its portfolio with Glam Bites, a collection of no-sugar gummies across three SKUs: Beauty Glow Skin (hyaluronic acid, vitamins C and E, sea moss, hydrolyzed marine collagen peptides), Hair Skin Nails (biotin, zinc, bamboo extract), and Skin Defense (astaxanthin, L-glutathione, green tea extract). The no-sugar gummy format targets consumers seeking convenience and a ritual experience without the sugar concerns of standard supplement gummies. Launch channel and depth of distribution not fully confirmed — likely CWH and Priceline. Source: NutraIngredients, February 2026.
Multiple Australian nutrition sources from March–April 2026 identify "fibre-maxxing" as a 2026 nutrition trend — defined as intentionally targeting 30+ grams of fibre daily for gut health, metabolic benefits, satiety, and inflammation reduction. Nutritionists are explicitly positioning fibre as complementary to (or in some circles displacing) protein's primary position. Globally, this is supported by gut health supplement search data: gut gummies +44%, postbiotics +55% (Glimpse, 2026). In Australian grocery, Woolworths Macro Chia Sesame Snaps won a 2026 POY in Healthy Snacking. Sources: HarmanHealth.com.au, March 2026; Unique Health Products, 2026; Glimpse supplement trends data.
"Smart collagen" is an emerging positioning frame in Australia for 2026: multi-benefit collagen supplements that go beyond cosmetic skin claims to deliver joint, gut, and bone health evidence. Nature's Way Collagen Mature Skin Shot (10-pack sachets) and Life Botanics Collagen + Shred at Coles signal mainstream grocery adoption. Vida Glow Natural Marine Collagen is ranked as Australia's top-rated collagen supplement in April 2026 review roundups. The global Naked Pharmacy identifies "accelerating and enhancing body's collagen production" (rather than simply adding collagen grams) as the key 2026 shift. Sources: Glow.com.au April 2026; The Naked Pharmacy 2026; Coles range data.
Multiple Australian nutrition commentators in early 2026 name creatine as among the evidence-based supplements "worth money" alongside omega-3 and magnesium — a clear departure from its previous association with male gym culture. Drivers cited: muscle preservation for women, cognitive function support, and healthy ageing applications. The GLP-1 muscle loss concern is accelerating clinical interest in creatine as a mitigation strategy. Globally, creatine search volume is rising rapidly. No specific AU pharmacy ranging announcements found for this period — signal is consumer-driven and nutritionist-endorsed rather than retailer-confirmed. Sources: HarmanHealth.com.au; BioHealth International 2026; Glimpse supplement trends.
Priceline was named a finalist for five 2026 Power Retail Awards: Top User Experience, Top Customer Experience, Top Loyalty Program, Top Direct Marketing Program, and Top Viral Moment — the last driven by a $10 Tuesday deal on No7 skincare that generated widespread consumer engagement in late November 2025. The $10 Tuesday format creates a weekly urgency trigger that drives app engagement, store traffic, and new product trial. 80% of Australians now shop multiple retailers monthly; loyalty programs (35%) and exclusive products (31%) are among the top four reasons for switching. Source: Pharmacy Daily, January 2026; Power Retail 2026.
Multiple Australian medical commentators (Abby Health, Crown Street Medical Centre) confirm oral semaglutide (pill-form GLP-1) is expected to receive Australian regulatory approval by late 2026 or early 2027. Eli Lilly's orforglipron — an oral GLP-1 in late-stage trials — demonstrated 12% average weight loss over 72 weeks. An oral format removes the injection barrier for many consumers, potentially significantly expanding the GLP-1 user base. This has direct implications for meal replacement, weight management supplements, and high-protein product categories. Sources: Abby Health April 2026; Crown Street Medical Centre 2026; IQVIA Obesity Outlook January 2026.
Coles range data shows Swisse Probiotic + Prebiotic Gummies (3B CFU, 45 pack) and Haircarebear Triple Strength Probiotic Gummies (50 pack) among the active gut health supplement listings. Nature's Way Kids Gummies Probiotic + Prebiotic (90 pack) represents the children's gut health occasion in grocery. Globally, gut gummies are growing +44% in search volume and postbiotics +55% (Glimpse 2026). The gummy format shift in probiotics mirrors the magnesium glycinate powder shift — consumers are ritualising daily supplement habits in more sensory, enjoyable formats. Sources: Coles.com.au range data; Glimpse supplement trends 2026.
[speculative] The global convergence of NAD+ skincare (topical retinoids with NAD+ boosters, e.g. Goop Youth Boost NAD+ Peptide Rich Cream) with oral supplement longevity is landing early in Australia via the NMN category and Swisse Nutra Cellular range. This positions the NMN opportunity not just as an internal supplement but as an entry point for a combined oral + topical NAD+ regime — a meaningful premium category with global precedent but no confirmed AU pharmacy ranging yet. Sources: Yahoo Beauty Best Launches 2026; Swisse Nutra Cellular range (NutraIngredients February 2026); Beauty Collective Australia, 2026.
Fill the Andrographis Void in Winter Immunity
Reformulate or launch cold/flu immune formulas that lead with Echinacea, Zinc + Vitamin C + Vitamin D3, Elderberry, or Olive Leaf Extract — explicitly positioning the product as Andrographis-free. The decision window is 8–12 weeks before winter peaks in June–July and shelf space resets occur.
Registered Sleep Supplement — Capture Melatonin Displacement
Consumers accessing melatonin products online are being redirected by TGA alert and iHerb withdrawal. Brands with registered (AUST L) sleep supplements containing magnesium glycinate, passionflower, L-theanine, or valerian should invest in consumer communications about their registered status. If melatonin rescheduling proceeds, be ready with an OTC melatonin product dossier.
NMN Brand Entry Before December 2027 Exclusivity Window Closes
The current NMN market is limited to brands that have secured secondary sponsor authorisation from SyncoZymes. The category is nascent and consumer education is low — brands that enter now with an education-led approach (rather than competing on price alone) will build category authority before the market opens more broadly in December 2027.
GLP-1 Adjacent Muscle + Metabolism Protocol Pack
Create a supplement protocol (protein + creatine + fibre) explicitly positioned for consumers on or considering GLP-1 weight management. The eligible population is material at national scale (→ see Market Signals), and even a fraction converting to companion supplementation represents significant commercial scale. The protocol frame (3 products working together) creates a basket-building opportunity.
Cellular Beauty Supplement at Pharmacy Mid-Tier
Swisse Nutra has established a premium cellular beauty tier at CWH. A mid-tier product ($35–$55) bridging collagen + NAD+ adjacent ingredients + gut health in a single daily supplement would sit below the premium cellular range but above standard collagen. The K-beauty entry at Priceline creates the shopper mindset for sophisticated inside-out beauty routines.
| Trend | AU Visibility | Entry Channel | Barriers | Timing |
|---|---|---|---|---|
| Oral GLP-1 Medications (Orforglipron, Oral Semaglutide) | Watch Not yet in AU market | GP prescription; PBS pending; consumer health adjacency across all channels | TGA regulatory review; PBS reimbursement timeline; cost (~$200–$700/month without subsidy) | Late 2026 – early 2027 likely; transformative consumer health category impact within 24 months of arrival |
| Postbiotics (Heat-killed probiotics, metabolites) | Early Limited AU ranging | Premium pharmacy and online health; eventual grocery gummy | Consumer education gap; ingredient cost; "what is a postbiotic" awareness very low in AU | 12–24 months to mainstream pharmacy shelf; global search +55% signals growing demand |
| NAD+ Topical + Oral Convergence Skincare | Visible — early NMN oral in AU; topical NAD+ not yet pharmacy-ranged | Premium pharmacy; Mecca / Sephora for topical; CWH for oral | TGA claims framework for topical cosmeceuticals; consumer education on inside-out protocol; pricing | Oral NMN launched; topical NAD+ likely 12–18 months from now in premium pharmacy |
| Exosome Skincare (topical cellular regeneration) | Early Not yet in mainstream AU pharmacy | Premium cosmeceutical pharmacy and aesthetics clinics first | Very high cost per SKU; TGA claims uncertainty for "cellular regeneration" claims; consumer education needed | 2–3 years from mainstream AU pharmacy ranging; early clinical exposure at dermatology now |
| Creatine for Women / Healthy Ageing (US mainstream trend) | Visible — building Nutritionist endorsement in AU 2026; not yet pharmacy-led | Pharmacy and online specialist; eventual grocery sports aisle crossover | Stigma (male gym ingredient perception); limited female-positioned AU products; dose format education | 6–12 months to first branded women's creatine pharmacy launch in AU; early mover advantage available |
| Tirzepatide (Mounjaro) as dominant GLP-1 in AU | Confirmed in AU market TGA-approved for weight management + T2D + sleep apnoea | GP prescription; PBS pending for weight management indication; not OTC | Cost; supply (ongoing international shortage); PBS access criteria pending PBAC recommendation | Consumer health adjacency impact now — muscle preservation and nutrition support products for tirzepatide users |
- Audit all Andrographis-containing listed medicines now — reformulation lead times are 3–6 months minimum
- Secure NMN secondary sponsor authorisation from SyncoZymes if entering the longevity category
- Build a GLP-1 adjacency claim narrative for protein, fibre, and creatine SKUs before oral semaglutide arrives
- Invest in Amazon AU product listings alongside CWH/Priceline — the digital share battle is real
- Move magnesium glycinate into powder formats — capsule-only brands are losing format relevance at Priceline
- Proactively communicate the Andrographis situation to consumers — pharmacist trust is highest when problems are addressed early, not hidden
- Review cold/flu bay planograms for winter 2026: which brands are Andrographis-free and which are not?
- Leverage NMN exclusivity at CWH while building consumer education infrastructure (digital, in-store, pharmacist-led)
- Health service integration (SiSU, cardiometabolic screening) accelerates supplement basket through identified need
- Extend loyalty promotional mechanics to supplements, not just beauty — the margin opportunity is significant
- Coles Ultralife POY double-win is a model to extend: identify 2–3 additional supplement subcategories for private label innovation
- Magnesium glycinate is over-branded — a grocery private label version at accessible price points would compete directly on the top-selling pharmacy SKU
- Gut health gummies (probiotics, prebiotics) are the next category where grocery private label can dominate
- Functional food + supplement co-positioning (e.g. high-fibre snacks alongside fibre supplements) is a unique grocery advantage pharmacy cannot replicate
- Woolworths' longevity platform partnership with Body+Soul should extend to supplement product endorsement and ranging decisions
- Monitor the TGA Andrographis decision (expected Q2–Q3 2026) as a category bellwether — the decision will reveal TGA's risk appetite for herbal listed medicines
- Track ACMS melatonin rescheduling outcome — a positive decision creates a new regulated OTC category worth significant commercial value
- Model the oral GLP-1 consumer health adjacency: which categories win (protein, creatine, fibre) and which lose (meal replacement, appetite suppressant) under a 30M+ GLP-1 user scenario
- Commission Australia-specific consumer research on the longevity supplement mindset — global data exists; AU-specific calibration is missing
- Zone 1 — NMN/Longevity: First-mover regulatory framework globally; category still in infancy; 12–18 month brand-building window before market opens in December 2027
- Zone 2 — GLP-1 Adjacent: population-scale eligibility is the largest quantified market opportunity in AU consumer health (→ see Market Signals); protein, fibre, and creatine brands with clinical adjacency positioning are strategically undervalued
- Zone 3 — Grocery Private Label Health: Coles Ultralife POY wins signal a structural trust shift (→ see Market Signals) — grocery supplement private label is now investor-grade quality signal, not a trade-down indicator
The regulatory calendar is now a commercial calendar.
The two most consequential commercial events of the March–May 2026 period are both TGA decisions: the Andrographis consultation and the melatonin rescheduling review. Brands that treat regulatory developments as compliance burdens rather than market intelligence signals are already behind. The Andrographis removal will create vacant shelf space in the highest-traffic cold/flu category during peak winter season (→ see Market Signals). The melatonin rescheduling, if it proceeds, will open a new OTC category worth tens of millions in annual sales. Neither event has come without warning; the commercial advantage goes to whoever prepared first.
Grocery private label has crossed the trust threshold.
Branded supplement companies must now compete on genuine clinical differentiation, not channel alone. The Coles Ultralife double POY win and Woolworths Macro's continued health growth reflect sustained private label innovation backed by consumer preference data (→ see Market Signals). A branded supplement that cannot articulate a meaningfully different clinical outcome, ingredient quality story, or dosage precision than a private label equivalent will face progressive margin compression at both Woolworths and Coles.
The GLP-1 adjacency opportunity is undercaptured.
With population-level GLP-1 eligibility confirmed at scale and the PBAC actively reviewing access (→ see Market Signals), the consumer health opportunity is to become indispensable to people using these medications. GLP-1 users lose muscle mass, may experience fatigue and reduced micronutrient intake, and require protein distribution across meals. Creatine, high-quality protein, fibre supplementation, and targeted micronutrients are the product categories with the most defensible GLP-1 adjacency.
Format is the new differentiation battleground.
The magnesium glycinate powder surge illustrates how format innovation creates category-within-category growth. As powder formats proliferate across pharmacy and begin entering grocery shelving, they risk commoditising on the same trajectory as tablets. The next format battleground is likely to be delivery precision: single-serve sachets, dual-phase capsules, and functional gummies with specific active ingredient dosing. Brands investing in format R&D now will have a 6–9 month shelf advantage over followers.
Digital first-party relationships are becoming structural.
Amazon AU's PPC share exceeding CWH's in health & beauty in March 2026 is the clearest evidence to date that the point of supplement discovery and consideration is shifting online. Brands that have built their commercial model entirely around pharmacy ranging face exposure as the consumer journey increasingly starts at Amazon, Google, TikTok, or Instagram. The investment case for direct-to-consumer digital capability, retailer media investment, or loyalty program integration has never been stronger in Australian consumer health.
Pharmacy's structural advantage this period is regulatory credibility: the TGA framework that approved NMN and is now consulting on Andrographis removal reinforces the role of pharmacist-stocked products as clinically trustworthy. CWH's deliberate decision to price NMN below global market rates is a category-building play that will benefit the whole pharmacy channel as consumer education grows. Priceline's investment in health service infrastructure (SiSU stations, pharmacist-led cardiometabolic checks) is similarly designed to widen the pharmacy value proposition beyond transactional product sales.
Grocery is winning on value and innovation velocity. The Coles Ultralife POY double-win is now the clearest private label proof point (→ see Market Signals), while Woolworths' Macro organic health brand growing 12% signals that shoppers are trading up within grocery private label, not just down to it. The functional food narrative — eating with a health goal — plays directly to grocery's strength in fresh food and category integration.
The channel divergence sharpening most in this period is digital: Amazon's 18.62% PPC share peak in Australian Retail Health & Beauty in March 2026 is the clearest competitive signal yet that online marketplaces are capturing health supplement consideration at scale. For brands, this creates pressure to invest in first-party relationship building through retail media and loyalty integration in both channels — not just shelf presence.